This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celldex Therapeutics Announces Upcoming Data Presentations At The Society For Immunotherapy Of Cancer And Society Of Neuro-Oncology Annual Meetings

Stocks in this article: CLDX

PHILLIPSBURG, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from two of its clinical programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent rindopepimut study, will be presented at two upcoming medical meetings, the Society for Immunotherapy of Cancer (SITC) and the Society of Neuro-Oncology (SNO), respectively. The Company also announced its communication plan around these data presentations.

SITC, November 7-10, National Harbor, Maryland

The embargo for all data to be presented at SITC lifts on Thursday, November 7 at 8:00 am ET, at which time abstracts will be published on the SITC website. Celldex has three abstracts on CDX-1127 that have been accepted for poster presentation (outlined below). Concurrent with the embargo lifting, Celldex will issue a press release that will include the preliminary data contained in the abstracts and updated data that will be presented in the poster sessions. Management will also hold a conference call at 8:30 am ET on Thursday, November 7 to review the data.

  • Data from the solid tumor arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.  
  • Data from the hematologic arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.  
  • Data from preclinical combination studies of CDX-1127 with chemotherapies and checkpoint inhibitors will be presented in a poster session entitled "Combination Therapies Augment the Anti-tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models" on Friday, November 8 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.

SNO, November 21-24, San Francisco, California

The embargo for abstracts lifts on Monday, November 11 at 7:00 am ET, at which time the abstracts will be published on the SNO website. Preliminary data from the ReACT study will be included in an abstract accepted for an oral presentation entitled "ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma." Celldex will present a more expansive, updated data package from the ReACT study in this oral session, which is scheduled for Sunday, November 24 from 10:20 am to 12:00 pm PT. The Company will issue a press release in concordance with this presentation. On Monday, November 25 at 8:30 am ET, management will also hold a conference call to review the data.

About Celldex Therapeutics, Inc.:

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldextherapeutics.com .

CONTACT: Company Contact:
         Sarah Cavanaugh
         Vice President of IR & Corp Comm
         Celldex Therapeutics, Inc.
         (781) 433-3161
         scavanaugh@celldextherapeutics.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs